Stocktoria
Kalaris Therapeutics, Inc. KLRS
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2020-07-30
Kalaris Therapeutics, Inc. statistics & valuation
Market cap$94.3M
P / B1.2×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Return on assets | -35.7% | -1122.5% | -99.8% | -60.9% | -60.0% |
| Return on equity | -55.1% | 71.6% | 423.0% | -75.1% | -76.3% |
| Current ratio | 12.23 | 0.11 | 6.61 | 9.99 | 6.69 |
Source: SEC EDGAR filings · CIK 0001754068 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.